Meso-Wharton P199 is a new generation injection treatment of high efficiency achieved by means of deep tissue repair at the cellular level. Meso-Wharton is developed by the U.S. ABG Lab LLC company and is produced on a pharmaceutical factory in South Korea. The medicine is approved by the U.S. Department of Health and Human Services.
Meso-Wharton is a treatment that is specifically designed for intensive rejuvenation of the skin of face and body in patients over 40 years of age.
The main active ingredient of the treatment is an embryonic peptide analogue (WhartonJellyPeptide Р199), produced by the synthetic method. It conduces to the synthesis of proper stem cells, elastin fibers, and hyaluronic acid.
Meso-Wharton is the only biorevitalizing treatment that works at the cellular level. It’s unique due to the presence of high molecular hyaluronic acid, amino acid complex, nucleic acids and vitamins in its formulation.
Meso-Wharton P199 not only moisturizes intensively the skin, but also stimulates actively the rejuvenation processes, conduces to proper stem cell expansion, which provides skin turnover and enrichment with vitamins and microelements.